A Strong Showing in MIS
Executive SummaryThe MIS roller coaster is heading up again. Just a couple of years ago, the slow acceptance of MIS procedures by general surgeons beyond laparoscopic cholecystectomy-in hernia repair, for example, or appendectomy-had everyone wondering just how muchpromise the MIS market holds.
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.